Plant-based cheese has a texture problem. It’s a known fact in food science and a constant complaint from consumers: the melt is wrong, the stretch is off. For Magi Richani, a lactose-intolerant engineer who grew up in Lebanon and worked in the oil industry, this wasn't just a market inefficiency. It was a personal annoyance that became a technical challenge. Her company, Nobell Foods, is betting that the answer isn't in better blends of starches and oils, but in growing the exact dairy proteins that give cheese its functional magic,directly inside a soybean.
Nobell, which has recently rebranded its parent company to Alpine Bio, has raised over $100 million, including a $75 million Series B in 2021 led by Bill Gates-backed Breakthrough Energy Ventures [Fast Company, July 2021] [AgFunderNews]. The core of the bet is casein, the primary protein in mammalian milk that forms micelles, giving cheese its unique ability to stretch and melt. By engineering soybeans to produce these proteins, Nobell aims to sidestep the animal entirely, creating a final product that is molecularly identical to dairy cheese but grown in a field.
The Protein as a Platform
The technical wedge is straightforward, if extraordinarily complex to execute. Most plant-based cheeses rely on fats, starches, and gums to approximate texture. Nobell’s approach is to produce the foundational ingredient,casein,and then use it in traditional cheesemaking processes. The company holds patents for producing dairy proteins, including casein, in soybeans, extracting them, and using them in cheese production [Tracxn].
This isn't fermentation, like some competitors use. It's molecular farming, turning a commodity crop into a bioreactor. The company calls its engineered soybeans "Cheesebeans" [GFI, 2025]. The potential advantage is twofold: first, it should, in theory, allow for a product that behaves indistinguishably from dairy cheese. Second, the agricultural inputs,soybeans, water, land,are theoretically more scalable and efficient than raising dairy herds, with the company claiming its process uses 90% less water and land and results in 70% fewer emissions than conventional dairy [Pear VC].
For a food service buyer or a CPG brand, the procurement question shifts from "Does this taste close enough?" to "Is this ingredient functionally equivalent and cost-competitive?" Nobell’s answer, still in the proving stage, is that it can be both.
The $75 Million Validation
The 2021 Series B round stands as a significant vote of confidence in both the technical premise and Richani’s leadership. The investor list reads like a who’s who of deep-tech and climate capital, alongside celebrity checks.
| Investor | Type | Notable For |
|---|---|---|
| Breakthrough Energy Ventures | Lead Investor | Bill Gates-backed climate tech fund |
| Andreessen Horowitz (a16z) | Venture Capital | Major tech and bio fund |
| Robert Downey Jr.'s FootPrint Coalition | Venture Capital | Celebrity climate fund |
| AgFunder | Venture Capital | Specialist agrifood tech investor |
| Fifty Years | Venture Capital | Early-stage deep tech & science |
The round’s size, at $75 million, is notable for a pre-revenue food ingredient company. It signals investor belief in a long, capital-intensive R&D and regulatory pathway. The capital was earmarked for scaling protein production, expanding the team, and navigating the U.S. Food and Drug Administration’s Generally Recognized as Safe (GRAS) self-affirmation process, a critical hurdle for any novel food ingredient [AgFunderNews].
From Shell Engineer to Food Tech CEO
Founder Magi Richani’s path is atypical for a food tech CEO, which may be the point. Her background is in project engineering at Shell, an experience that likely informs a systems-level, capital-project mindset suited to building a new agricultural supply chain from the ground up [Fast Company, July 2021]. The founder-market fit is personal; her own lactose intolerance was a direct motivator [The Times Tech Podcast].
She started the company in 2016 and went through Y Combinator in 2017, positioning Nobell early in the current wave of alternative protein investment. The recent rebrand to Alpine Bio as the parent company suggests an ambition beyond cheese. The company has indicated it can also produce other functional proteins like lactoferrin in its platform, pointing to a broader pipeline of plant-grown animal-identical ingredients [AgFunderNews].
The Road to the Grocery Aisle
Traction for a deep science company like this is measured in patents, pilot harvests, and regulatory filings, not monthly active users. Nobell harvested its first casein-containing soybean crop in 2024 [GFI, 2025]. Its stated goal is to begin public tastings of its animal-free mozzarella in 2025, with a commercial launch to follow [Breakthrough Energy Ventures Job Board, 2026].
The company is currently hiring for roles like Pilot Plant Associate, indicating it is moving from lab-scale research toward pilot production [BevJobs/Breakthrough Energy]. The commercial model appears to be B2B2C: Nobell (operating as Alpine Bio) will produce the plant-based casein ingredient, which could then be sold to food manufacturers or used under its own Nobell Foods brand for consumer products.
The Realistic Competitive Set
Nobell does not compete with every plant-based cheese brand on the shelf. Its realistic competitors are the few other companies attempting to produce animal-identical dairy proteins through precision fermentation or cellular agriculture, not those working with plant blends.
- Perfect Day. The incumbent in animal-identical dairy proteins, using precision fermentation (microflora) rather than plants. It has achieved regulatory approval and market presence for its whey protein, which is used in ice cream, protein powder, and cream cheese. Its model is B2B ingredient supply. Perfect Day represents the most direct comparison in business model and scientific ambition.
- New Culture. Another precision fermentation company focused specifically on casein for mozzarella cheese. It is also pursuing a B2B ingredient model and is in the process of scaling production and seeking regulatory approval.
- Climax Foods. Takes a different, data-science driven approach to plant-based cheese, using machine learning to discover optimal blends of existing plant proteins, fats, and flavors without engineering novel proteins. It competes for the same end consumer but with a fundamentally different technical stack.
The ideal customer for Nobell’s ingredient is a large food manufacturer or pizza chain for whom cheese functionality,specifically melt and stretch,is non-negotiable, but for whom sustainability and supply chain volatility are growing concerns. Think of a national pizza brand or a prepared foods company. For them, a drop-in, functionally identical casein that decarbonizes their supply chain could command a premium, provided the price per pound gets close enough to conventional dairy.
The Counterfactuals
The bet is large, the science is hard, and the clock is ticking. The capital raised needs to fund the journey from pilot harvest to cost-competitive commodity-scale production. The risks are not trivial.
- The Cost Curve. The ultimate test is whether plant-grown casein can reach price parity with dairy-derived casein. Dairy is a heavily subsidized industry with decades of optimization behind it. Nobell’s process involves genetically engineering seeds, contracting with farmers, building novel extraction facilities, and navigating a non-commodity supply chain. The capital efficiency of this path versus fermentation-based approaches is unproven at scale.
- The Regulatory Timeline. GRAS self-affirmation is a rigorous process requiring extensive safety data. Any delays or requests for additional studies from the FDA could push out the commercialization timeline and burn more capital.
- The Adoption Cycle. Even with approval and scale, convincing conservative food manufacturers to reformulate with a novel ingredient is a long sales cycle. The first major contract will be a crucial milestone to prove the model.
The company’s answer to these challenges is its patented platform and its head start in molecular farming for casein. The rebrand to Alpine Bio and the mention of other proteins like lactoferrin suggest a strategy to amortize the foundational plant-engineering platform across multiple high-value ingredients, improving the overall unit economics.
For now, the proof will be in the tasting. If the mozzarella sampled in 2025 truly stretches and melts like the dairy standard, Nobell will have cleared its first major consumer hurdle. Then the real commercial work,scaling, costing, and selling into the long procurement cycles of global food companies,begins.
Sources
- [Fast Company, July 2021] This startup just raised $75 million to make a more cheesy plant-based cheese | https://www.fastcompany.com/90657375/this-startup-just-raised-75-million-to-make-a-more-cheesy-plant-based-cheese
- [AgFunderNews] Plant-based cheesemaker Nobell Foods nets $75m from a16z, AgFunder & Breakthrough Energy | https://agfundernews.com/nobell-foods-nets-75m-from-a16z-agfunder-breakthrough-energy
- [Tracxn] Nobell Foods Company Profile | https://www.crunchbase.com/organization/alpine-roads
- [Pear VC] Nobell Foods Investment Profile | Not available
- [GFI, 2025] GFI Article on Molecular Farming | https://gfi.org
- [The Times Tech Podcast] Interview with Magi Richani | Not available
- [Breakthrough Energy Ventures Job Board, 2026] Nobell Foods Job Posting | https://bevjobs.breakthroughenergy.org/companies/nobell-foods/jobs/37431812-pilot-plant-associate
- [AgFunderNews] Molecular farming startup Nobell Foods rebrands as Alpine Bio, secures 10th US patent | https://agfundernews.com/exclusive-molecular-farming-startup-nobell-foods-rebrands-as-alpine-bio-secures-10th-us-patent